One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease
Suveen Angraal(University of Missouri–Kansas City), Kim G. Smolderen(Yale University), Vittal Hejjaji(Saint Luke's Hospital), Yuanyuan Tang(Saint Luke's Hospital), Kensey Gosch(Saint Luke's Hospital), Carlos Mena‐Hurtado(Mount Sinai Hospital), Eric A. Secemsky(Beth Israel Deaconess Medical Center), Jan M.M. Heyligers(Elisabeth-TweeSteden Ziekenhuis), Rudolf Tutein Nolthenius(Albert Schweitzer Ziekenhuis), Herbert D. Aronow, J. Dawn Abbott(Brown University), Gregory L. Moneta(Oregon Health & Science University), Robert Fitridge(Royal Adelaide Hospital), Peter Soukas(Northwestern University), Manesh R. Patel(Duke University), Christopher J. White(Ochsner Medical Center), John A. Spertus(Saint Luke's Health System)
Cited by 20
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary
|Circulation|2012|2.4k
(untitled)
|Edinburgh Research Explorer (University of Edinburgh)|0|2.3k
Global vascular guidelines on the management of chronic limb-threatening ischemia
|Journal of Vascular Surgery|2019|1.9k